Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Sorafenib in advanced hepatocellular carcinoma.
In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo. Expand
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.
The present document gives up-dated guidelines for the current clinical practice, and an overview of those aspects that should be the target of future clinical research. Expand
Prognosis of hepatocellular carcinoma: the BCLC staging classification.
A new staging system is proposed, the Barcelona Clinic Liver Cancer (BCLC) staging classification, that comprises four stages that select the best candidates for the best therapies currently available, based on prognostic factors obtained from studies performed years ago. Expand
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
Chemoembolisation improved survival of stringently selected patients with unresectable hepatocellular carcinoma and was associated with a significantly lower rate of portal-vein invasion than conservative treatment. Expand
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
A group of experts developed a set of guidelines aimed at providing a common framework for the design of clinical trials in HCC and adapted the concept of viable tumor-tumoral tissue showing uptake in arterial phase of contrast-enhanced radiologic imaging techniques-to formally amend RECIST, referred to herein as the modified RECIST assessment (mRECIST). Expand
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
Chemoembolization improves survival of patients with unresectable HCC and may become the standard treatment and only low‐quality scale trials suggested 1‐year improvement in survival. Expand
Design and endpoints of clinical trials in hepatocellular carcinoma.
- J. Llovet, A. D. Di Bisceglie, +8 authors G. Gores
- Journal of the National Cancer Institute
These guidelines provide a common framework for designing trials to facilitate comparability of results, and randomized phase 2 trials with a time-to-event primary endpoint, such as time to progression, are pivotal in clinical research on HCC. Expand
Meta-analysis shows that only chemoembolisation improves survival in well-selected patients with unresectable HCC, and Resection is indicated among patients who have one tumour and well-preserved liver function. Expand
Findings of randomised trials of sorafenib have shown survival benefits for individuals with advanced hepatocellular carcinoma, suggesting that molecular-targeted therapies could be effective in this chemoresistant cancer. Expand
Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation
In conclusion, a proper selection of candidates for resection promotes better results than transplantation, in which the results are significantly hampered by the growing incidence of drop‐outs because of the increasing waiting time. Expand